JAAHA Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Reimer, M.
Right arrow Articles by Warnick, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reimer, M.
Right arrow Articles by Warnick, L.
Journal of the American Animal Hospital Association, Vol 35, Issue 5, 384-391
Copyright © 1999 by American Animal Hospital Association


Articles

Immune-mediated hemolytic anemia: 70 cases (1988-1996)

ME Reimer, GC Troy, and LD Warnick

Survival times and mortality rates in dogs with idiopathic immune-mediated hemolytic anemia (IMHA) have been infrequently reported in the literature. This study evaluates survival and mortality in a large group of dogs with IMHA. The association of age, sex, and breed with IMHA was evaluated by comparing affected dogs to control dogs admitted to the hospital during the same time period. Treatment regimens were reviewed to determine the effects of different agents upon survival of dogs with IMHA during hospitalization and after discharge. Median survival times for each treatment group were 57 days (prednisone), 28 days (prednisone, cyclophosphamide), 974 days (prednisone, azathioprine), 15 days (prednisone, cyclophosphamide, azathioprine), and one day (no treatment). Overall mortality rate in the population of dogs studied was 70%. Twenty-nine (41.4%) dogs either died or were euthanized while hospitalized. Forty-one (59%) dogs were discharged from the hospital. Of the dogs discharged, 10 died within the first month, another five died within three months, and another five died within a year of discharge due to assumed complications of therapy or relapses of IMHA.


This article has been cited by other articles:


Home page
Vet PatholHome page
P. F. Moore, V. K. Affolter, and W. Vernau
Canine Hemophagocytic Histiocytic Sarcoma: A Proliferative Disorder of CD11d+ Macrophages.
Vet. Pathol., September 1, 2006; 43(5): 632 - 645.
[Abstract] [Full Text] [PDF]


Home page
Journal of the American Animal Hospital AssociationHome page
M. F. Thompson, J. C. Scott-Moncrieff, and M. B. Brooks
Effect of a Single Plasma Transfusion on Thromboembolism in 13 Dogs With Primary Immune-Mediated Hemolytic Anemia
J. Am. Anim. Hosp. Assoc., November 1, 2004; 40(6): 446 - 454.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the American Animal Hospital Association.